MARKETS
Earnings

Lakefront Biotherapeutics Q2 EPS $0.29 Beats $(13.52) Estimate, Sales $21.624M Beat $7.210M Estimate

Aug 10, 2026 · 04:27 PM ET· updated 1h ago

Lakefront Biotherapeutics (NASDAQ:LKFT) reported quarterly earnings of $0.29 per share which beat the analyst consensus estimate of $(13.52) by 102.14 percent. This is a 120 percent increase over losses of $(1.45) per

Share
Why It Matters

Lakefront Biotherapeutics made way more money than experts thought it would in the last three months, and its sales were also much bigger than expected. When a company surprises people like this in a good way, it's a sign to watch if they might keep doing well.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.